Ralser, Damian J.
Herr, Emmanuelle
de Vos, Luka
Kulcsár, Zsófi
Zarbl, Romina
Klümper, Niklas
Gielen, Gerrit H.
Maas, Alexander Philippe
Hoffmann, Friederike
Dietrich, Jörn
Kuster, Pia
Mustea, Alexander
Glodde, Nicole
Kristiansen, Glen
Strieth, Sebastian
Landsberg, Jennifer
Dietrich, Dimo
Funding for this research was provided by:
University Medical Center Bonn (UKB) BONFOR program (2021-1A-14, 2022-1A-08, 2022-4-18, 2020-2A-12)
German Society of Urology (KIN1/FE-19)
German Cancer Aid (70113307)
Novartis MAYA Research Initiative 2021 (S2TAF-80)
Universitätsklinikum Bonn
Article History
Received: 16 November 2022
Accepted: 29 May 2023
First Online: 1 June 2023
Declarations
:
: The study was approved by the Institutional Review Board.
: Not applicable.
: DJR, DD, and NK have received financial support (speaker’s honoraria and travel expense reimbursement) from Novartis. NK has received financial support (speaker’s honoraria or travel expense reimbursement) from Astellas. JL is a consultant/ advisory board member of Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, and Roche. DD is in part funded by the Novartis MAYA Research Initiative 2021 (grant no. S2TAF-80). DD owns patents and patent applications on biomarker technologies and methylation of immune checkpoint genes as predictive and prognostic biomarkers. The patents are licensed to Qiagen GmbH (Hilden, Germany). DD is a consultant of Qiagen. The University Hospital Bonn (PI DD) received research funding from Qiagen.